FDA Investigates BHA Over Cancer Risk Concerns

  fda-investigates-bha-over-cancer-risk-concerns.html
  Food and Wine on Tue, Feb 10th, 2026 by Associated Press
      Locale: UNITED STATES

Washington D.C. - February 10th, 2026 - The U.S. Food and Drug Administration (FDA) today announced a significantly expanded review of Butylated Hydroxyanisole (BHA), a widely used synthetic antioxidant and preservative found in numerous food products. This move comes on the heels of mounting scientific evidence suggesting a potential link between BHA exposure and increased cancer risk, sparking debate among regulators, food manufacturers, and consumer advocacy groups.

BHA, designated as GRAS (Generally Recognized As Safe) for decades, has been a staple in preserving fats and oils in processed foods, preventing rancidity and extending shelf life. It's present in everything from cereals and chewing gum to potato chips and cosmetics. However, recent longitudinal studies, notably a five-year research project concluded last month by the National Toxicology Program (NTP), have challenged this long-held assumption.

The NTP study, which tracked a cohort of over 50,000 participants with varying BHA exposure levels through dietary intake, revealed a statistically significant correlation between high BHA consumption and the incidence of squamous cell carcinomas in the forestomach of laboratory animals. While extrapolating animal data to humans is always complex, the study's findings, combined with several earlier in vitro studies indicating BHA's potential to induce DNA damage, have prompted the FDA to move beyond a simple 'reassessment' to a full-scale investigation.

"We take all potential health risks seriously," stated Dr. Eleanor Vance, Director of the FDA's Center for Food Safety and Applied Nutrition, in a press conference this morning. "The preliminary data warrants a deeper look at the totality of the evidence, encompassing both animal and human studies. We are not issuing a recall at this time, but we are committed to a thorough and transparent review process." The FDA indicated that the investigation will incorporate data from international regulatory bodies, including the European Food Safety Authority (EFSA), which has previously conducted its own limited review of BHA.

Consumer advocacy groups, however, are calling for more decisive action. The "Safe Food Now" coalition issued a statement demanding an immediate suspension of BHA's GRAS status and urging consumers to actively avoid products containing the preservative. "For too long, the FDA has relied on outdated safety assessments," said Maria Rodriguez, lead advocate for the coalition. "The science is becoming increasingly clear: BHA poses a potential cancer risk, and the public deserves to be protected. We need a proactive approach, not just another study."

The food industry, predictably, is taking a more cautious stance. The Food Manufacturers Association (FMA) released a statement acknowledging the FDA's review but emphasizing the critical role BHA plays in maintaining food quality and preventing spoilage. "BHA is a cost-effective and efficient preservative," a spokesperson for the FMA stated. "Eliminating it would require substantial reformulation of many products, potentially leading to increased food waste and higher prices for consumers. We are confident that the FDA will arrive at a science-based conclusion that balances public health with the practical needs of the food supply."

The FDA's expanded review will focus on several key areas, including: identifying safe levels of BHA exposure; exploring potential synergistic effects with other food additives; and investigating the bioavailability of BHA in various food matrices. The agency is also commissioning independent research to assess the impact of BHA on human gut microbiome and its potential influence on cancer development. Furthermore, the FDA is actively researching and evaluating potential alternative preservatives, such as natural antioxidants like tocopherols (Vitamin E) and rosemary extract, though scalability and cost-effectiveness remain significant hurdles.

The implications of this review extend beyond just the food industry. BHA is also used in cosmetics, packaging materials, and even pharmaceutical products. Any significant changes to its regulatory status could have ripple effects across multiple sectors. The FDA expects to complete its comprehensive review within the next 18-24 months and will provide regular updates to the public as new information becomes available.